Related Experiment Videos

NMR relaxation studies with MnDPDP

T E Southon1, D Grant, A Bjørnerud

  • 1Nycomed Imaging AS, Oslo, Norway.

Abstract

Insights

Mangafodipir trisodium (MnDPDP) and manganese chloride (MnCl2) both enhance MRI relaxation rates. MnDPDP offers cardiovascular safety without sacrificing efficacy for T1-weighted imaging.

Area of Science:

  • Magnetic Resonance Imaging (MRI)
  • Medical Imaging Agents
  • Pharmacology

Background:

  • Mangafodipir trisodium (MnDPDP) is a potential tissue-specific MRI contrast agent.
  • Manganese chloride (MnCl2) is a known MRI contrast agent.
  • Comparing the efficacy and optimal administration of MnDPDP versus MnCl2 is crucial for clinical application.

Purpose of the Study:

  • To compare the efficacy of MnDPDP as a tissue-specific MR agent against MnCl2.
  • To evaluate the impact of different doses and administration rates of MnDPDP.
  • To gather data for optimizing MRI pulse sequences with MnDPDP.

Main Methods:

  • Determined dose-response for R1 and R2 relaxation rates at 0.47 T for MnDPDP and MnCl2.
  • Measured manganese concentrations in rat liver and pig organs (liver, pancreas, heart, adrenals).
  • Utilized computer simulations to model effects of tissue Mn concentration and TR on signal intensity and contrast-to-noise ratios.

Main Results:

  • Both MnDPDP and MnCl2 showed a positive dose-response for R1 and tissue Mn concentration in rat liver and pig organs.
  • R2 relaxation rates showed minimal response to both agents.
  • Rat liver Mn concentration correlated positively with R1, irrespective of Mn form or administration rate.

Conclusions:

  • MnDPDP provides cardiovascular safety over MnCl2 without compromising efficacy for increasing R1 at the clinical dose of 5 μmol/kg MnDPDP.
  • Minimal changes in R2 suggest limited impact on T2-weighted images.
  • The study provides a basis for selecting appropriate pulse sequences for MnDPDP-enhanced MRI.

Related Concept Videos